title: Trapping effect on a small molecular drug with vascular-disrupting agent CA4P in rodent H22 hepatic tumor model: in vivo magnetic resonance imaging and postmortem inductively coupled plasma atomic emission spectroscopy.
abstract: The aim of the present study is to verify the trapping effect of combretastatin A-4-phosphate (CA4P) on small molecular drugs in rodent tumors. Mice with H22 hepatocarcinoma were randomized into groups A and B. Magnetic resonance imaging (MRI) of T1WI, T2WI, and DWI was performed as baseline. Mice in group A were injected with Gd-DTPA and PBS. Mice in group B were injected with Gd-DTPA and CA4P. All mice undergo CE-T1WI at 0 h, 3 h, 6 h, 12 h, and 24 h. Enhancing efficacy of the two groups on CE-T1WI was compared with the signal-to-noise ratio (SNR) calculated. Concentrations of gadolinium measured by ICP-AES in the tumor were compared between groups. On the early CE-T1WI, tumors were equally enhanced in both groups. On the delayed CE-T1WI, the enhancing effect of group A was weaker than that of group B. The SNR and the concentration of gadolinium within the tumor of group A were lower than that of group B at 6 h, 12 h, and 24 h after administration. This study indicates that CA4P could improve the retention of Gd-DTPA in the tumor and MRI allowed dynamically monitoring trapping effects of CA4P on local retention of Gd-DTPA as a small molecular drug.
authors.affiliation: Laboratory of Translational Medicine, Jiangsu Province Academy of Traditional Chinese Medicine , Nanjing , PR China .
authors.forename: Meng
authors.initials: M
authors.lastname: Gao
authors.forename: Nan
authors.initials: N
authors.lastname: Yao
authors.forename: Dejian
authors.initials: D
authors.lastname: Huang
authors.forename: Cuihua
authors.initials: C
authors.lastname: Jiang
authors.forename: Yuanbo
authors.initials: Y
authors.lastname: Feng
authors.forename: Yue
authors.initials: Y
authors.lastname: Li
authors.forename: Bin
authors.initials: B
authors.lastname: Lou
authors.forename: Fei
authors.initials: F
authors.lastname: Peng
authors.forename: Ziping
authors.initials: Z
authors.lastname: Sun
authors.forename: Yicheng
authors.initials: Y
authors.lastname: Ni
authors.forename: Jian
authors.initials: J
authors.lastname: Zhang
mesh_terms: D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000473:pathology; D003287:Contrast Media / Q000008:administration & dosage / Q000493:pharmacokinetics; D004195:Disease Models, Animal; D019786:Gadolinium DTPA / Q000008:administration & dosage* / Q000493:pharmacokinetics; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008279:Magnetic Resonance Imaging / Q000379:methods; D008297:Male; D051379:Mice; D013054:Spectrophotometry, Atomic / Q000379:methods; D013267:Stilbenes / Q000494:pharmacology*; D013997:Time Factors; D014018:Tissue Distribution
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D003287:Contrast Media; D013267:Stilbenes; C058728:fosbretabulin; D019786:Gadolinium DTPA
keywords: Combretastatin A-4-phosphate (CA4P); inductively coupled plasma atomic emission spectroscopy (ICP-AES); magnetic resonance imaging (MRI); trapping effect; tumor